Oncternal Therapeutics (ONCT) shares tumbled 33% in recent Monday premarket activity after it said in a regulatory filing that Nasdaq believes the company is a "public shell" and will adopt more "stringent" criteria for its listing after its Nov. 14 announcement of workforce reduction.
Actuate Therapeutics (ACTU) stock fell 21%, extending Friday's loss.
Akoustis Technologies (AKTS) shares slipped 20%, continuing the previous session's loss.
Macy's (M) stock fell more than 3% after it reported preliminary fiscal Q3 results and said it was delaying its quarterly earnings release due to an "issue" it identified regarding delivery expenditures in one of its accrual accounts.
Comments